医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Macrogen Selects GenoLogics’ Clarity LIMS to Strengthen X-Genome and Clinical Sequencing Services

2014年10月21日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea & SAN FRANCISCO

The personalized medicine biotechnology company Macrogen (www.macrogen.com) has announced it has licensed Clarity LIMS from GenoLogics Life Sciences Software (www.genologics.com), a leading provider of LIMS specifically designed for omics labs, to support its whole-genome sequencing and clinical sequencing services.

Clarity is GenoLogics’ laboratory information management system built specifically for the needs of clinical or research genomics and mass spec laboratories to provide end-to-end sample tracking, automation, preconfigured workflows, and superior usability.

Using Clarity LIMS, Macrogen plans to strengthen its support for researchers and clinical customers by automating the analysis of whole-genome sequencing and clinical sequencing services and systematically managing the strict requirements of clinical environments.

In January 2014, Macrogen became an early adopter of Illumina’s HiSeq X™ Ten platform to pioneer new diagnostic and genomics services and strengthen the foundation for personalized medicine. The company also launched the X-Genome (Xpressway to Genome) service for researchers who conduct large-scale whole-human genome sequencing based studies. Moreover, Macrogen has established a U.S. subsidiary, Macrogen Clinical Laboratory, Inc. (MCL), which set up a CLIA (Clinical Laboratory Improvement Amendments)-certified clinical laboratory last year to provide clinical sequencing based healthcare services for physicians and patients. Macrogen plans to use Clarity LIMS in its MCL subsidiary first.

“The US subsidiary MCL selected GenoLogics’ Clarity LIMS after recognizing that it is the optimum means of providing whole-genome sequencing services in close cooperation with the Korean Headquarters while satisfying the strict requirements of CLIA,” said Kim Hyung-tae, CEO of Macrogen. “The X-Genome service, based on the HiSeq X Ten system for whole-human genome sequencing, will help Macrogen strengthen its competitive edge in the existing research market and establish its leading position in the clinical sequencing service market. ”

“Clarity LIMS improves the overall efficiency and results of genome research,” states Michael Ball, CEO of GenoLogics. “We are pleased to support Macrogen with automation and support for their X-Genome and clinical sequencing services.”

About Macrogen

Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. Macrogen Inc. has been dedicated to providing a reliable and efficient service of DNA Sequencing and bioinformatics with profound knowledge and extensive experience over 17 years. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services. We serve over +17,000 customers from academic research and industry in 120 countries around the globe and have subsidiary companies in USA, Japan and Europe. Macrogen is headquartered in Seoul, South Korea.

About GenoLogics

GenoLogics develops the industry-leading laboratory information management system (LIMS) for life sciences organizations. Clarity LIMS helps labs gain efficiencies and throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations. Whether your lab is regulated or unregulated, big or small, Clarity LIMS will streamline your lab operations so that you can focus on advancing healthcare. Founded in 2002 and privately held, GenoLogics is based in San Francisco, CA. www.genologics.com

CONTACT

GenoLogics Life Sciences Software
Lisa Owen, Communications Manager
1-250-483-7011
lisa.owen@genologics.com
or
Macrogen,
Inc.
YongHwan Kang, Communications Manager
82-2-2113-7113
snatch@macrogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表